Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
This is a fascinating compound for researchers, a novel tri-agonist that targets glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
(1996, Journal of Endocrinology) reported IGF-1 LR3 was 1.5-2x more potent than equimolar native IGF-1 for body weight gain, organ growth, and anti-catabolic effects when continuously infused in normal and dexamethasone-treated rats
AI-assisted evaluation is a methodological innovation
LB is supported by DP220101361 on behalf of the Australian Research Council, LFS is supported by FT190100462 on behalf of the Australian Research Council, JR and the Xenopus laevis Research Resource for Immunobiology are supported by R24-AI-059830 on behalf of the National Institute of Allergy and Infectious Diseases).
US$ 24.72
US$ 21.97
US$ 20.34
US$ 28.11
US$ 25.27
US$ 26.75
